Literature DB >> 16166330

Medullary thyroid carcinoma arises in the absence of prolactin signaling.

Cécile Kedzia1, Ludovic Lacroix, Nabahet Ameur, Thierry Ragot, Paul A Kelly, Bernard Caillou, Nadine Binart.   

Abstract

Prolactin, a pituitary hormone, exerts pleiotropic effects in various cells. These effects are mediated by a membrane receptor highly expressed in many tissues. To analyze prolactin effects on the thyroid gland, we first identified prolactin receptor (PRLR) mRNAs by in situ hybridization. To further evaluate the physiologic relevance of PRLR actions in the thyroid in vivo, we used PRLR knockout mice. Whereas the histologic structure of thyroid of PRLR-null mice was not disturbed, we show that T4 levels are lower in null animals (13.63 +/- 2.98 versus 10.78 +/- 2.25 pmol/L in null mice), confirming that prolactin participates in the control of thyroid metabolism. To further investigate thyroid effects in mice, we measured body temperature and thyroid-stimulating hormone in young and adult male and/or female PRLR-null mice and their normal siblings. Surprisingly, in null animals, we saw medullary thyroid carcinoma (MTC) arising from parafollicular C cells producing calcitonin. The incidence of these carcinomas attained 41% in PRLR-null mice, whereas this malignant tumor occurs sporadically or as a component of the familial cancer syndrome in humans. This finding suggests that PRLR-null mice could represent a valuable animal model for MTC, which could be compared with existing MTC models. These observations suggest a possible link between the appearance of this carcinoma and the absence of prolactin signaling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16166330     DOI: 10.1158/0008-5472.CAN-04-3937

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

Review 1.  Thyroid C-Cell Biology and Oncogenic Transformation.

Authors:  Gilbert J Cote; Elizabeth G Grubbs; Marie-Claude Hofmann
Journal:  Recent Results Cancer Res       Date:  2015

2.  The role of Cdk5 in neuroendocrine thyroid cancer.

Authors:  Karine Pozo; Emely Castro-Rivera; Chunfeng Tan; Florian Plattner; Gert Schwach; Veronika Siegl; Douglas Meyer; Ailan Guo; Justin Gundara; Gabriel Mettlach; Edmond Richer; Jonathan A Guevara; Li Ning; Anjali Gupta; Guiyang Hao; Li-Huei Tsai; Xiankai Sun; Pietro Antich; Stanley Sidhu; Bruce G Robinson; Herbert Chen; Fiemu E Nwariaku; Roswitha Pfragner; James A Richardson; James A Bibb
Journal:  Cancer Cell       Date:  2013-10-14       Impact factor: 31.743

3.  Prolactin receptor in primary hyperparathyroidism--expression, functionality and clinical correlations.

Authors:  Felix Haglund; Ming Lu; Vladana Vukojević; Inga-Lena Nilsson; Adam Andreasson; Mensur Džabić; Robert Bränström; Anders Höög; C Christofer Juhlin; Catharina Larsson
Journal:  PLoS One       Date:  2012-05-11       Impact factor: 3.240

4.  Expression of prolactin receptor and prolactin in normal and malignant thyroid: a tissue microarray study.

Authors:  Patrícia Costa; Ana Luísa Catarino; Fernanda Silva; Luís G Sobrinho; Maria João Bugalho
Journal:  Endocr Pathol       Date:  2006       Impact factor: 4.056

5.  Prolactin receptor signaling is essential for perinatal brown adipocyte function: a role for insulin-like growth factor-2.

Authors:  Say Viengchareun; Nathalie Servel; Bruno Fève; Michael Freemark; Marc Lombès; Nadine Binart
Journal:  PLoS One       Date:  2008-02-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.